CTOs on the Move

ALOG Corporation

www.alogcorp.com

 
Maintain, repair, and install chemical and biological detection equipment for the Department of Defense working with Force Protection. Responsibilities include, ensuring that lower-level employees are trained to meet current and forecasted support requirements; providing technical advice; submitting input for on-demand reports and trend analysis; and interfacing with the Prime Contractor and supported units as required. Applying advanced technical knowledge of electronic principles in determining equipment malfunctions, and applies skill in restoring equipment operations. Read and comprehend drawings, diagrams, and manuals pertaining to the test and repair of pneumatic, hydraulic, and electronic equipment. Exercises independent judgment in performing such tasks as ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.alogcorp.com
  • 3077 Leeman Ferry Rd SW
    Huntsville, AL USA 35801
  • Phone: 256.319.2066

Executives

Name Title Contact Details

Similar Companies

World Gym Fitness Center

World Gym Fitness Center is a Rocky Mount, NC-based company in the Business Services sector.

Romancecompass.com

100% Legitimate Online dating service for women seeking men and those men who looking for Slavic brides. You can find Ukrainian & Russian brides, Russian and Ukrainian single girls, women for marriage.

Jewish Federation of Southern Arizona

The Jewish Federation of Southern Arizona brings the Jewish community together to help those in need and to strengthen and preserve the Jewish people.

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, founded in 2006. Formerly known as Miragen Therapeutics, the company rebranded in January 2021. Viridian is dedicated to discovering, developing, and commercializing treatments for serious and rare diseases, utilizing its expertise in antibody discovery and protein engineering. The company’s product pipeline includes Veligrotug (VRDN-001), a monoclonal antibody in Phase 3 clinical trials for thyroid eye disease, and VRDN-003, a next-generation IGF-1R monoclonal antibody also in Phase 3 trials for the same condition. Additionally, Viridian is developing a portfolio of engineered anti-FcRn inhibitors, such as VRDN-006 and VRDN-008, aimed at treating various autoimmune diseases. Viridians mission is to deliver transformative therapies for patients with underserved diseases, emphasizing innovation and patient-centricity.